What are the approved tirzepatide injection sites?
Tirzepatide is administered by subcutaneous injection — into the adipose (fatty) tissue directly beneath the skin, not into muscle. Three body sites have been designated as appropriate injection locations:
| Site | Specific location | Ease of self-injection | Key note |
|---|---|---|---|
| Abdomen | Lower abdomen, ≥2 inches from navel | High — most common first choice | Avoid periumbilical area; variable absorption there |
| Upper thigh | Outer portion, middle third of thigh length | High — good subcutaneous depth in most patients | Avoid inner thigh and area behind knee |
| Upper arm | Outer upper arm (vaccination site area) | Lower — requires mirror, auto-injector, or assistance | Auto-injector pens simplify arm injection |
Clinical data from the SURPASS and SURMOUNT trial programs did not identify meaningful absorption differences between these three sites. The choice between sites is primarily about practical access and patient comfort.
Why does injection site rotation matter?
Repeated injections at the same location cause lipohypertrophy — the development of firm, fatty nodules under the skin. Lipohypertrophic tissue looks and feels different from normal subcutaneous fat and has one important clinical consequence: it absorbs medication unpredictably.
Injecting into lipohypertrophic tissue can produce erratic blood levels of tirzepatide, undermining the dose precision that makes the weekly injection schedule effective. Patients who inject into the same spot for weeks or months sometimes report unexpected nausea spikes or apparent dose variability — lipohypertrophy is a common underlying cause.
The rotation protocol is straightforward: change the injection site with each weekly dose. A simple approach is to cycle through the abdomen, thigh, and arm on successive weeks. Within the abdomen, further rotate the specific injection point, moving systematically around the eligible area rather than returning to the same spot.
How do you inject tirzepatide correctly? Step-by-step technique
The injection technique is as important as the injection location. A correctly executed subcutaneous injection deposits medication reliably in fatty tissue rather than in muscle (too deep) or skin layers (too shallow). Follow your clinician’s specific guidance — these steps reflect standard subcutaneous technique as directed in a supervised protocol.
- Choose and rotate your injection site. Select one of the three approved sites (abdomen, outer thigh, outer arm) and rotate the specific location with each weekly dose to prevent lipohypertrophy.
- Allow tirzepatide to reach room temperature. Remove the vial or pen from the refrigerator approximately 30 minutes before injection. Inspect the solution — it should be clear to slightly yellow and particle-free. Do not use if cloudy or discolored.
- Clean the site with an alcohol swab. Let the area air-dry for at least 15 seconds. Wet alcohol can sting and does not improve sterility.
- Prepare the dose as directed by your clinician. Never mix tirzepatide with other injectable medications in the same syringe.
- Inject at the correct angle and depth. Insert the needle at 90 degrees for 4 mm needles; at 45 degrees for longer needles in leaner patients. Inject slowly into the subcutaneous fatty tissue — not into muscle or a vein. Use a pinch technique at leaner sites if directed.
- Withdraw and dispose safely. Apply light pressure with a dry cotton ball if needed. Do not rub the site. Place the used needle in a sharps container immediately.
What should you avoid when injecting tirzepatide?
Several injection practices increase risk and should be explicitly avoided:
- Within 2 inches of the navel: Periumbilical tissue has variable depth and connective tissue density. Absorption is less predictable, and the area is more likely to produce injection-site reactions.
- Into areas with existing lipohypertrophy: If you notice hard nodules or irregular fatty tissue at a previous injection site, retire that location from rotation and allow the tissue to recover.
- Into bruised, red, or inflamed skin: These indicate local tissue disruption that will affect absorption and increase the risk of infection.
- Into scar tissue: Scars have altered vascularity and connective tissue architecture. Absorption through scar tissue is unpredictable.
- Into muscle: Intramuscular injection of tirzepatide (going too deep) produces faster absorption and potentially higher peak blood levels — increasing the likelihood of nausea and GI side effects. Subcutaneous delivery produces the slower, sustained absorption profile tirzepatide is designed for.
How do you manage injection-site reactions?
Mild injection-site reactions — redness, itching, or a small bump at the injection point — are common with subcutaneous peptide and GLP-1 injections and typically resolve within a few days. In the SURPASS clinical trials, injection-site reactions were among the reported adverse events, though they were generally mild and did not result in treatment discontinuation at meaningful rates.
If reactions are consistent across sites, last more than a week, or are accompanied by swelling, warmth, or systemic symptoms (fever, rash), contact your prescribing clinician. Persistent reactions may indicate an issue with injection technique, needle length, or in rare cases, a sensitivity that warrants protocol adjustment.
How should you store and handle tirzepatide before injection?
Tirzepatide must be refrigerated (36–46°F / 2–8°C) and protected from light. Remove it from the refrigerator approximately 30 minutesbefore injection to bring it to room temperature — cold injections are more uncomfortable and may slightly affect the viscosity of the solution. Do not freeze, microwave, or warm the vial in hot water.
Inspect the solution before each injection. Tirzepatide solution should be clear to slightly yellow and free of particles. Do not use if the solution is cloudy, discolored, or contains visible particulate matter. Discard expired or damaged vials per the disposal instructions from your pharmacy.
Frequently asked questions
Where do you inject tirzepatide?
Tirzepatide is injected subcutaneously — into the fatty tissue just beneath the skin. The three approved injection sites are the abdomen (at least 2 inches from the navel), the upper thigh (outer portion), and the upper arm (outer portion). Each site offers comparable absorption in clinical data.
What is the best injection site for tirzepatide?
Clinical guidance does not designate one site as universally superior. Abdomen, thigh, and upper arm are all acceptable. The practical consideration is access and consistency: sites you can inject accurately and comfortably are better for adherence. Some patients prefer the abdomen for visibility; others prefer the thigh for ease of self-injection.
Should I rotate tirzepatide injection sites?
Yes. Rotation within and across sites is important to prevent lipohypertrophy — the buildup of fatty tissue that forms when the same spot is injected repeatedly. Lipohypertrophy affects drug absorption and can cause irregular medication levels. Rotate at minimum weekly, ideally using a systematic pattern across the available sites.
How deep should a tirzepatide injection be?
Tirzepatide is a subcutaneous injection, meaning the needle should reach the fatty tissue under the skin but should not penetrate muscle. Standard subcutaneous needles (4mm to 8mm depending on body composition) are appropriate. Your prescribing clinician or pharmacist will advise on the correct needle length for your body.
Can I inject tirzepatide in the arm?
Yes. The outer upper arm is one of three approved injection sites for tirzepatide. Self-injection into the arm is technically more challenging than the abdomen or thigh. Some patients use an auto-injector pen or have a family member assist with arm injections.
What should I avoid when injecting tirzepatide?
Avoid injecting into the navel (within 2 inches), skin that is bruised, tender, scarred, or affected by lipohypertrophy. Avoid muscle tissue — tirzepatide is subcutaneous, not intramuscular. Never inject into a vein. Change the injection site each week to avoid tissue damage at a single location.